Mass General Brigham and Dana-Farber Cancer Institute collaborating with BEEAH Group to advise on a new, patient-centered health care system

Strategic collaboration supports BEEAH in creating Jawaher Boston Medical District in Sharjah, United Arab Emirates

Boston, MA, May 16, 2023 (GLOBE NEWSWIRE) — Mass General Brigham and Dana-Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development of the Jawaher Boston Medical District, a state-of-the-art health care system designed to deliver world-class, patient-centered care through innovation, technology, and sustainability. Mass General Brigham and Dana-Farber Cancer Institute are strategic partners, serving in an advisory capacity, on the project in Sharjah, United Arab Emirates, which includes a multi-specialty flagship hospital for integrated, cutting-edge care.

The collaboration combines the depth and breadth of clinical expertise and innovation from Mass General Brigham and Dana-Farber Cancer Institute, with BEEAH’s vision to create a sustainable, advanced, patient-centered health system designed to deliver care to patients within – and beyond – hospital walls. BEEAH Group was founded in 2007 to tackle sustainability challenges in Sharjah and improve quality of life.

Focused on serving the unique needs of the people of Sharjah and the region, the Jawaher Boston Medical District will offer patients access to the latest clinical expertise across a wide variety of integrated clinical specialties, including lifestyle medicine and prevention, oncology, women’s health, pediatrics, cardiovascular, neurosciences, behavioral health, and rehabilitation medicine. In addition to medical and research expertise, Mass General Brigham and Dana-Farber Cancer Institute will also collaborate with BEEAH Group to advise on best practices in workforce training, development, and public education to the community, with attention to developing local talent.

Mass General Brigham and Dana-Farber Cancer Institute are advising BEEAH Group in their development of multiple facilities, comprising the flagship hospital and ambulatory clinics across Sharjah, with integrated, innovative, and digital solutions, including app-based care and hospital-at-home.

“Mass General Brigham has a deep history of global collaboration aimed at serving and improving the lives of patients around the world,” said Raymond W. Liu, MD, Vice President, Mass General Brigham Global Advisory.  “In collaborating with BEEAH, we hope to contribute our decades of expertise to their development of a unique, innovative vision for a health system that builds on medicine’s leading edge, with an eye to the future.”

“Dana-Farber, a world leader in cancer treatment and research, is committed to advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases locally and globally,” said Adam Reich, Vice President of Business Initiatives at Dana-Farber Cancer Institute. “We are pleased to work with BEEAH and extend our expertise to this collaboration as part of our mission to enhance access to expert cancer care and reduce the burden of cancer worldwide.”

By leveraging its expertise in quality-of-life solutions in Sharjah and the Middle East, BEEAH will create a new destination for the health, wellness and quality of life for the people of Sharjah and the region focused on patient outcomes and experience gleaned from a robust academic ecosystem pioneered, developed and refined over two centuries by Mass General Brigham and Dana-Farber Cancer Institute clinicians.

By pooling their combined medical, research and sustainability expertise, Mass General Brigham, Dana-Farber Cancer Institute and BEEAH will develop innovative technologies, diagnostics, delivery models and patient care, ultimately fostering research, directly benefitting patients globally and providing valuable cross-institutional learnings in the United States. The outcome will enable BEEAH to create a comprehensive patient-centered health care system for the people of Sharjah and the UAE, integrating healthcare solutions into homes, schools, workplaces, and communities to help all patients and their families live healthier lives.

“By partnering with Mass General Brigham and Dana-Farber Cancer Institute, BEEAH Group is entering the healthcare industry and adding a new dimension to our purpose of pioneering a sustainable quality of life for the people of Sharjah, the UAE, and beyond,” said Khaled Al Huraimel, Group CEO of BEEAH Group. “Drawing from the expertise of our partners in Boston, we look forward to creating not just an integrated health network, but a future-ready healthcare ecosystem. The Jawaher Boston Medical District will provide patients in Sharjah access to world-class healthcare closer to home, while also serving as a hub for the development of cutting-edge treatments and medical advancement.”

The project draws from Mass General Brigham and Dana-Farber Cancer Institute’s medical and research expertise, as well as BEEAH Group’s experience collaborating and innovating with international partners to create facilities that are sustainable, digitally-enabled and centered around the comfort and convenience of occupants.

Following a meeting of representatives from Mass General Brigham, Dana-Farber Cancer Institute and BEEAH Group, Sheikha Jawaher Al Qasimi, Wife of the Ruler of Sharjah and Chairperson of BEEAH Group, and Meghan Gregonis, United States General Consul in Dubai, the Jawaher Boston Medical District in Sharjah was approved to move forward.

About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit www.massgeneralbrigham.org.

About Dana-Farber Cancer Institute 
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber is the only hospital with a top 4 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.

For more information, please visit www.dana-farber.org.

About BEEAH Group
BEEAH Group is the region’s leading sustainability and digitalisation expert, renowned for ground-breaking environmental innovations and smart solutions for future-ready cities. Recognising sustainability and technology as the pillars of a modern economy, BEEAH Group has invested in a comprehensive, full-circle strategy for the future. BEEAH Group operates in the industries of waste management, renewable energy, technology, consulting, education, transport, real estate and healthcare. Raising the bar for the quality of life in the region, BEEAH Group businesses continue to set industry benchmarks in sustainable, smart solutions and help countries across the region create and execute their roadmap for a socially responsible future. The Group currently operates in the UAE, Egypt and KSA. For more information, please visit www.beeahgroup.com and connect on LinkedInInstagramFacebook and Twitter @beeahgroup

Noah Brown
Mass General Brigham
617-643-3907
[email protected]

GlobeNewswire Distribution ID 8840712

DIS INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Walt Disney Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – DIS

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of The Walt Disney Company (NYSE: DIS) between December 10, 2020 and November 8, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2023.

SO WHAT: If you purchased Disney securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Disney class action, go to https://rosenlegal.com/submit-form/?case_id=16164 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The Complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Disney+ was suffering decelerating subscriber growth, losses, and cost overruns; (2) the true costs incurred in connection with Disney+ had been concealed by Disney executives by debuting certain content intended for Disney+ initially on Disney’s legacy distribution channels and then making the shows available on Disney thereafter to improperly shift costs out of the Disney+ segment; (3) Disney Media and Entertainment Distribution (“DMED”) had made platform distribution decisions based not on consumer preference, consumer behavior, or the desire to maximize the size of the audience for the content as represented, but based on the desire to hide the full costs of building Disney+ ‘s content library; (4) Disney was not on track to achieve even the reduced 2024 Disney paid global subscriber and profitability targets, such targets were not achievable, and such estimates lacked a reasonable basis; and (5) defendants had materially misrepresented the actual performance of Disney+, the sustainability of Disney+’s historical growth trends, the profitability of Disney+, and the likelihood that Disney could achieve its 2024 Disney+ subscriber and profitability targets. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Disney class action, go to https://rosenlegal.com/submit-form/?case_id=16164 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 8840685

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sprit AeroSystems Holdings Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPR

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Spirit AeroSystems Holdings, Inc. (NYSE: SPR) between April 8, 2020 and April 13, 2023, both dates inclusive (the “Class Period”), of the important July 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Spirit AeroSystems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Spirit AeroSystems class action, go to https://rosenlegal.com/submit-form/?case_id=15844 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Spirit lacked effective production quality controls; (2) that, as a result, Spirit incorrectly installed fittings designed to join the aft fuselage to the vertical tail for some Boeing 737 Max airplanes that Spirit sent to Boeing; (3) that, as a result, Spirit would have to develop an inspection and repair procedure for the affected fuselages; (4) that the foregoing would negatively impact Spirit’s financial results; and (5) that as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Spirit AeroSystems class action, go to https://rosenlegal.com/submit-form/?case_id=15844 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 8840669

Zoom Partners with Anthropic to Expand Federated Approach to AI

Zoom announces investment in Anthropic to support research roadmaps and build steerable AI systems; Anthropic’s AI model will help strengthen Zoom’s federated approach across its platform, including Zoom Contact Center integrations

SAN JOSE, Calif., May 16, 2023 (GLOBE NEWSWIRE) — Today, Zoom announced a strategic partnership with and investment in Anthropic, an AI safety and research company working to build reliable, interpretable, and steerable AI systems. The collaboration with Anthropic will further bolster Zoom’s federated approach to AI by allowing Anthropic’s AI assistant, Claude, to be integrated with Zoom’s platform (which includes Team Chat, Meetings, Phone, Whiteboard, Zoom IQ), starting with Zoom Contact Center.

“Anthropic’s Constitutional AI model is primed to provide safe and responsible integrations for our next-generation innovations, beginning with the Zoom Contact Center portfolio. With Claude guiding agents toward trustworthy resolutions and powering self-service for end-users, companies will be able to take customer relationships to another level,” said Smita Hashim, chief product officer for Zoom. “Partnering with Anthropic also furthers our commitment to providing customers with our federated approach to AI, optimized to deliver outstanding customer experience outcomes. Additionally, with our investment, we are advancing leading-edge companies like Anthropic and helping to drive innovation in the Zoom ecosystem and beyond.”

“Partnering with a leading collaboration platform like Zoom allows us to put robust, steerable AI into the hands of more people and unlock its potential to help streamline everyday processes,” said Dario Amodei, CEO and co-founder of Anthropic. “We look forward to working together to showcase Anthropic’s capabilities and our joint commitment to enhancing productivity through intelligent solutions.”

Zoom’s federated approach to AI leverages its own proprietary AI models, along with those from leading AI companies — such as Anthropic — and select customers’ models. With this flexibility to incorporate multiple types of models, Zoom can provide the most value for its customers’ diverse needs. Zoom will be able to customize these models to perform better for a customer, based on their specific business needs.

As the next step in evolving the Zoom Contact Center portfolio, (Zoom Virtual Agent, Zoom Contact Center, Zoom Workforce Management), Zoom plans to incorporate Anthropic AI throughout its suite, improving end-user outcomes and enabling superior agent experiences. The Zoom Contact Center suite of solutions elevates the quality of customer experiences through better self-service and the ability to accurately understand customer intent. It intelligently guides customers to the best resolution, surfaces actionable insights that managers can use to coach their agents, and improves productivity by providing a unified communications and contact center experience. In the near future, Zoom will also use AI to provide the right resources to agents, so customers receive exceptional service experiences regardless of their reason for calling.

Announced today, Zoom Ventures has made an investment in Anthropic, strengthening the relationship between both companies. Anthropic’s research and development aims to create steerable, trustworthy, and responsible large-scale AI systems. Zoom did not disclose the amount of the investment.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
[email protected]

GlobeNewswire Distribution ID 8840480

ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

BUFFALO, NY / ACCESSWIRE / May 16, 2023 / ZeptoMetrix® is excited to introduce PROtrol TM, a new line of products designed for antigen-based diagnostic methods. These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.

PROtrol is the only whole organism reference material to provide complete testing data. Each lot of product is supplied with the protein concentration and TCID50 value, which minimizes qualification testing. PROtrol provides better reproducibility, which optimizes the use of financial spending and processing time through the decreased need for repeat testing.

ZeptoMetrix logo

“The rapid expansion in development of antigen-based assays has highlighted some quality challenges. Inactivated, whole organism controls designed specifically for antigen tests can equip manufacturers with the tools they need to better evaluate the performance of their assays, leading to higher quality tests on the market,” said Dr. Karuna Sharma, Vice President & Chief Scientific Officer.

PROtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Isolate: USA-WA1/2020* is the first member of this product line (PROSARS(COV2)-587). As we move beyond the COVID-19 pandemic, ZeptoMetrix will continue to grow the PROtrol product line, providing high-quality controls to assay manufacturers seeking to expand access to inexpensive and easy-to-use diagnostics.

“The launch and expansion of PROtrol enhances our position as the partner of choice for diagnostic test developers,” said Evangeline Gonzalez, President of Antylia Diagnostics division. “As we work with our diagnostic partners, ZeptoMetrix is pleased with the role that PROtrol plays to give patients around the world more access to diagnostic testing.”

More information on how to order the new PROtrol and additional ZeptoMetrix products can be found at: https://www.zeptometrix.com

About ZeptoMetrix®
ZeptoMetrix® is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

Links:
* (PROSARS(COV2)-587): product page
https://www.zeptometrix.com/products/protrolt-sars-cov-2-isolate-usa-wa1-2020-1-ml

Contact Information

Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417

Related Files

PROSARS(COV2)-587 Product Insert.pdf
ZeptoMetrix Launches PROtrol.pdf

SOURCE: ZeptoMetrix

Impulse Dynamics Announces 9,000th Patient Milestone Achieved With CCM® Therapy for Heart Failure

Momentum Continues as Depth of Clinical Experience Expands Worldwide

MARLTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a worldwide milestone achievement with the 9,000th patient receiving the Optimizer® system for the treatment of moderate HF. The Optimizer system is the only device approved by the U.S. Food and Drug Administration (FDA) in the United States to deliver CCM therapy. Dr. Steven Gubin, a cardiologist and the President of Stern Cardiovascular, is part of the care team that completed the procedure at Baptist Memorial Hospital-Memphis, offering CCM therapy to a patient living with the debilitating effects of HF. This milestone highlights the momentum building globally for CCM therapy, using the Optimizer platform to improve quality of life in HF patients.

“I am excited to have a new therapy option for heart failure patients,” said Dr. Gubin, who has been practicing for 30 years. “One of my heart failure patients, Aubretta Bean, who is a cancer survivor, continued to have symptoms despite her compliance with guideline-directed medical therapy for heart failure. She let me know that she felt better almost immediately after receiving the implant and continues to improve daily. It has been extremely rewarding to see such improvement in her quality of life. Her lab work four weeks later showed her BNP (a common test to diagnose heart failure) decreased by 81%, which is consistent with improvement in her heart failure symptoms.”

“Before my CCM implant, I could not walk from one room to the other without gasping for air. It was like being underwater and trying to breathe through a straw,” said Aubretta Bean. “Heart failure changed my life so quickly. You might think housework is a chore, but when you can’t make your bed or do the dishes, you realize how quickly you would love to do that again. Now after my Optimizer implant, I can do all these things! I look forward to planning my days again and not just trying to get through them. I have eight grandkids and two great-grandkids that I can travel to see!”

Drs. Eric Johnson, David Lan, and Chris Ingelmo are all electrophysiologists at Stern Cardiovascular that have treated ten patients at Baptist Memorial Hospital-Memphis with CCM therapy since March 2023. Dr. Chris Ingelmo completed the milestone procedure for the 9,000th patient treated with CCM therapy. The results have been encouraging, with significant improvement in patient symptoms.

“We are inspired by such stories highlighting the potential for clinicians to use CCM therapy to make a positive impact on HF patients’ lives,” said Simos Kedikoglou, MD, CEO of Impulse Dynamics. “The growing cadence of implants and the emergence of such inspiring stories reinforces our commitment to delivering meaningful advances in CCM technology and clinical data.”

CCM therapy is now available in 44 countries, and the technology has continued to advance based on the needs of patients and physicians. The latest generation of Impulse Dynamic’s proprietary Optimizer platform is the Optimizer Smart Mini, which offers a rechargeable battery with 20-year battery life and a smaller size designed to make the implant procedure faster and easier for patients and physicians.

About the Optimizer® and CCM® Therapy

The Optimizer Smart system delivers CCM therapy — the company’s proprietary technology — to the heart. CCM therapy has been designed by Impulse Dynamics to significantly improve the heart’s contraction, allowing more oxygen-rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6-minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM is the brand name for cardiac contractility modulation — the non-excitatory electrical pulses delivered by the implantable Optimizer device to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM helps the heart contract more forcibly. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer-reviewed journal articles.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. CCM therapy has proven safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, the continued momentum for the adoption of CCM therapy and use of the Optimizer Smart system globally; the ability for CCM therapy and our products and technology to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer system and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; company’s ability to expand and grow its business into new geographic markets; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for its Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

Rohan More, Global Vice President of Marketing
Impulse Dynamics
856-642-9933
[email protected]

Harriss Currie, Chief Financial Officer
Impulse Dynamics
856-642-9933
[email protected]

Ian Segal, Public Relations Manager
Impulse Dynamics
856-642-9933
[email protected]

GlobeNewswire Distribution ID 8839792